These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14982804)

  • 1. In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.
    Vera-Cabrera L; Ochoa-Felix EY; Gonzalez G; Tijerina R; Choi SH; Welsh O
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1037-9. PubMed ID: 14982804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of new antimicrobials against Nocardia brasiliensis.
    Vera-Cabrera L; Gonzalez E; Choi SH; Welsh O
    Antimicrob Agents Chemother; 2004 Feb; 48(2):602-4. PubMed ID: 14742215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.
    Gordon KA; Rhomberg PR; Jones RN
    J Clin Microbiol; 2003 Aug; 41(8):3967-9. PubMed ID: 12904431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
    Pérez-Vázquez M; Román F; Aracil B; Cantón R; Campos J
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3539-41. PubMed ID: 14576114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.
    Yong D; Yum JH; Lee K; Chong Y; Choi SH; Rhee JK
    Antimicrob Agents Chemother; 2004 Jan; 48(1):352-7. PubMed ID: 14693566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oxazolidinone-quinolone hybrid antimicrobials.
    Gordeev MF; Hackbarth C; Barbachyn MR; Banitt LS; Gage JR; Luehr GW; Gomez M; Trias J; Morin SE; Zurenko GE; Parker CN; Evans JM; White RJ; Patel DV
    Bioorg Med Chem Lett; 2003 Dec; 13(23):4213-6. PubMed ID: 14623004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.
    Jones RN; Holliday NM; Rhomberg PR
    J Clin Microbiol; 2015 Feb; 53(2):657-9. PubMed ID: 25411167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
    Pereyre S; Renaudin H; Bébéar C; Bébéar CM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3165-8. PubMed ID: 15273141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1140-2. PubMed ID: 12604557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.
    Hubschwerlen C; Specklin JL; Baeschlin DK; Borer Y; Haefeli S; Sigwalt C; Schroeder S; Locher HH
    Bioorg Med Chem Lett; 2003 Dec; 13(23):4229-33. PubMed ID: 14623007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 1998 May; 42(5):1274-7. PubMed ID: 9593166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
    Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in-vitro activity of temafloxacin, against gram-positive bacteria.
    Mandell LA; Lawrence T; Rotstein C; Gorzynski EA; Beam TR; Amsterdam D
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():15-24. PubMed ID: 1664826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
    Jones RN; Moet GJ; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT; Mutnick AH; Jones RN; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.